Stephen K. Brannan - Dec 9, 2022 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol
KRTX
Transactions as of
Dec 9, 2022
Transactions value $
-$964,819
Form type
4
Date filed
12/12/2022, 04:04 PM
Previous filing
Nov 10, 2022
Next filing
Jan 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $26.4K +3.64K +24.25% $7.27* 18.6K Dec 9, 2022 Direct
transaction KRTX Common Stock Sale -$730K -3.64K -19.51% $200.76 15K Dec 9, 2022 Direct F1
transaction KRTX Common Stock Options Exercise $12.5K +1.36K +9.09% $9.20* 16.4K Dec 9, 2022 Direct
transaction KRTX Common Stock Sale -$274K -1.36K -8.33% $200.76 15K Dec 9, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -3.64K -51.15% $0.00 3.47K Dec 9, 2022 Common Stock 3.64K $7.27 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -1.36K -10.71% $0.00 11.4K Dec 9, 2022 Common Stock 1.36K $9.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2 This option vested as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of August 8, 2018.
F3 This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.